Contraceptives Market to Reach $34.7 Billion by 2035

Contraceptives market was valued at $19.2 billion in 2025 and is projected to reach $34.7 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026-2035).The market is primarily driven by the steady increase in adoption rates supported by national family planning initiatives and improved access to modern methods. Government data indicates that the contraceptive prevalence rate in India increased from 54% to nearly 67% between recent survey periods, reflecting a significant rise in usage among the reproductive population. This improvement is further supported by a rise in demand satisfied for family planning, which has reached approximately 76%, exceeding global targets set for 2030. In addition, long-term trends show that contraceptive usage has expanded from about 40.7% in the early 1990s to over 66% in recent years, indicating sustained behavioral shifts. High awareness levels, with nearly universal knowledge of contraception among individuals, continue to reinforce adoption across both urban and rural populations. These factors collectively translate into consistent demand for both short-term and long-acting contraceptive products, forming a stable revenue base for manufacturers.

Browse the full report description of “Contraceptives Market Size, Share & Trends Analysis Report by Type (Contraceptive Drugs, and Contraceptive Devices), by Distribution Channel (Hospital Pharmacy, Retail Stores, E-Commerce, and Others), by End-User (Hospitals, Household, Clinics, and Ambulatory Surgical Centers), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/contraceptives-market-size

The market is further supported by the presence of a measurable unmet need, which continues to sustain future demand for contraceptive products. Government and UN data suggest that unmet need for contraception remains close to 8–9%, indicating a sizeable population that still requires access to modern solutions. This gap directly contributes to incremental market expansion as healthcare systems focus on improving accessibility and product availability. Moreover, a significant proportion of users rely on publicly supplied contraceptives, with approximately 68% obtaining products through government healthcare channels, ensuring large-scale distribution. The combination of increasing adoption rates and remaining unmet demand creates a balanced growth environment, where both volume expansion and penetration improvement continue to drive the market.

Innovation Leaders Transforming the Contraceptives Market

The key players in the contraceptives market include Bayer AG, Pfizer Inc., Organon & Co, Reckitt Benckiser Group plc, Church & Dwight Co., Inc., among others. These companies are advancing innovation in contraceptive solutions through the development of improved hormonal formulations, long-acting reversible devices, and user-friendly delivery systems, enabling effective pregnancy prevention while enhancing safety, convenience, and compliance. Continuous focus on product differentiation, including low-dose therapies and non-hormonal alternatives, is supporting broader adoption across diverse population groups. Manufacturers are also strengthening accessibility through expanded distribution channels and affordable product offerings, aligning with increasing demand for reliable and personalized reproductive health solutions.

• In January 2026, Organon & Co. received U.S. FDA approval to extend the usage duration of its NEXPLANON (etonogestrel implant) from three to five years. Clinical data confirmed continued efficacy with no reported pregnancies during the extended period and no new safety concerns. The update also includes a strengthened safety program to ensure proper insertion and removal procedures.

• In October 2025, The World Health Organization granted prequalification to a generic self-injectable contraceptive (DMPA-SC) developed by Incepta Pharmaceuticals, improving access to affordable contraception. This approval reduces reliance on a single supplier and supports wider availability in low- and middle-income countries. The product enables self-administration, enhancing convenience and user autonomy.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Distribution Channel
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Bayer AG, Pfizer Inc., Organon & Co, Reckitt Benckiser Group plc, Church & Dwight Co., Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Contraceptives Market Report Segment

By Type

• Contraceptive Drugs
• Contraceptive Devices

By Distribution Channel

• Hospital Pharmacy
• Retail Stores
• E-Commerce
• Others

By End-User

• Hospitals
• Household
• Clinics
• Ambulatory Surgical Centers

Global Contraceptives Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/contraceptives-market-size